Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial
Posted inGastroenterology news Oncology

Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial

The phase 3 TORCH trial demonstrates that adding selective radiofrequency ablation after transarterial chemoembolization significantly improves progression-free and overall survival in patients with unresectable liver-confined hepatocellular carcinoma, with acceptable safety.